Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ANI Pharmaceuticals, Inc. (ANIP)
USD81.23
+0.68 (+0.84%)
US NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
210 Main Street West 56623
Baudette, MN, US
Baudette, MN, US
CEO
Nikhil Lalwani
Website
anipharmaceuticals.com
IPO
2000-05-05
CIK 1023024 ISIN US00182C1036
Description
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| BioSante | BPAX | 2009-08-07 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD81.23
+0.68 (+0.84%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
358.2K
Beta
0.44
Float Shares
19.37M
Free Float %
85.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.00% | -9.41% | +1.52% | +2.77% | -5.97% | +0.71% | +28.23% | +94.47% | +137.10% | +74.73% | -62.81% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
81.23
Low
124.00
+52.7%
Consensus
124.00
+52.7%
Median
124.00
+52.7%
High
124.00
+52.7%
DCF (Unlevered)
1,107.16
+1,263.1%
DCF (Levered)
1,428.52
+1,658.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
88% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 5 |
108.60
+33.7%
|
| All Time | 11 |
91.00
+12.0%
|
Quality scores
Altman Z-Score
2.69
Grey zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
4 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+43.8% ★ Q1'26: +20.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+419.2% ★ Q1'26: +85.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+16.8% ★ Q1'26: +22.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+13.1% ★ Q1'26: +16.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+16.3% ★ Q1'26: +19.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+9.9% Q1'26: +7.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.57× Q1'26: 1.37× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 5 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
55.97M
est: 52.56M (+6.5%)
|
76.32M
est: 76.44M (-0.2%)
|
128.62M
est: 131.40M (-2.1%)
|
176.84M
est: 181.60M (-2.6%)
|
201.58M
est: 197.94M (+1.8%)
|
206.55M
est: 210.37M (-1.8%)
|
208.48M
est: 205.37M (+1.5%)
|
216.14M
est: 211.60M (+2.1%)
|
316.39M
est: 306.90M (+3.1%)
|
486.82M
est: 538.95M (-9.7%)
|
614.38M
est: 599.19M (+2.5%)
|
883.37M
est: 867.39M (+1.8%)
|
1.11B
1.08B – 1.16B
+28.5% YoY
|
1.24B
1.17B – 1.29B
+11.4% YoY
|
1.31B
1.30B – 1.32B
+5.6% YoY
|
1.42B
1.37B – 1.47B
+8.0% YoY
|
1.57B
1.52B – 1.62B
+10.6% YoY
|
| EBITDA |
24.04M
est: -4.98M (+582.7%)
|
39.64M
est: 32.05M (+23.7%)
|
56.31M
est: 14.46M (+289.4%)
|
57.16M
est: 52.65M (+8.6%)
|
69.10M
est: 67.23M (+2.8%)
|
60.74M
est: 56.45M (+7.6%)
|
28.13M
est: 22.60M (+24.5%)
|
3.12M
est: 23.28M (-86.6%)
|
25.04M
est: 16.36M (+53.0%)
|
106.60M
est: 222.76M (-52.1%)
|
63.12M
est: 247.65M (-74.5%)
|
207.27M
est: 358.50M (-42.2%)
|
460.83M
446.06M – 477.99M
+28.5% YoY
|
513.53M
483.82M – 534.75M
+11.4% YoY
|
542.13M
538.45M – 545.82M
+5.6% YoY
|
585.52M
566.75M – 607.33M
+8.0% YoY
|
647.31M
626.57M – 671.42M
+10.6% YoY
|
| EBIT |
20.17M
est: -19.71M (+202.3%)
|
32.70M
est: 30.07M (+8.7%)
|
33.96M
est: -7.99M (+524.9%)
|
29.23M
est: 26.33M (+11.0%)
|
34.81M
est: 34.46M (+1.0%)
|
16.12M
est: 14.85M (+8.6%)
|
-16.51M
est: -12.49M (-32.2%)
|
-44.14M
est: -12.87M (-242.9%)
|
-34.61M
est: -81.97M (+57.8%)
|
46.81M
est: 216.98M (-78.4%)
|
-4.61M
est: 241.23M (-101.9%)
|
115.85M
est: 349.20M (-66.8%)
|
448.87M
434.49M – 465.60M
+28.5% YoY
|
500.21M
471.27M – 520.88M
+11.4% YoY
|
528.07M
524.48M – 531.67M
+5.6% YoY
|
570.33M
552.06M – 591.58M
+8.0% YoY
|
630.52M
610.32M – 654.01M
+10.6% YoY
|
| Net Income |
28.75M
est: -5.90M (+587.1%)
|
15.38M
est: 13.92M (+10.4%)
|
3.93M
est: 78.37M (-95.0%)
|
-1.08M
est: -1.89M (+43.0%)
|
15.49M
est: 14.97M (+3.5%)
|
6.09M
est: 5.36M (+13.8%)
|
-22.55M
est: 70.45M (-132.0%)
|
-42.60M
est: 66.84M (-163.7%)
|
-47.90M
est: -7.50M (-538.5%)
|
18.78M
est: 25.59M (-26.6%)
|
-18.52M
est: 105.96M (-117.5%)
|
78.34M
est: 160.21M (-51.1%)
|
197.19M
193.89M – 200.49M
+23.1% YoY
|
232.71M
216.41M – 249.01M
+18.0% YoY
|
272.46M
260.23M – 284.69M
+17.1% YoY
|
289.71M
277.64M – 303.74M
+6.3% YoY
|
322.81M
309.36M – 338.44M
+11.4% YoY
|
| SGA |
17.94M
est: 19.26M (-6.9%)
|
21.16M
est: 19.69M (+7.4%)
|
27.83M
est: 48.15M (-42.2%)
|
31.58M
est: 29.78M (+6.0%)
|
44.06M
est: 43.20M (+2.0%)
|
55.84M
est: 54.23M (+3.0%)
|
64.99M
est: 75.26M (-13.6%)
|
84.29M
est: 77.54M (+8.7%)
|
124.04M
est: 155.44M (-20.2%)
|
161.70M
est: 202.67M (-20.2%)
|
249.64M
est: 225.32M (+10.8%)
|
317.75M
est: 326.18M (-2.6%)
|
419.28M
405.85M – 434.90M
+28.5% YoY
|
467.23M
440.20M – 486.54M
+11.4% YoY
|
493.26M
489.90M – 496.61M
+5.6% YoY
|
532.73M
515.66M – 552.58M
+8.0% YoY
|
588.95M
570.08M – 610.89M
+10.6% YoY
|
| EPS |
2.61
est: 1.18 (+121.2%)
|
1.34
est: 2.70 (-50.3%)
|
0.34
est: 4.06 (-91.6%)
|
-0.09
est: 3.88 (-102.4%)
|
1.33
est: 4.99 (-73.3%)
|
0.51
est: 5.16 (-90.1%)
|
-1.88
est: 3.65 (-151.6%)
|
-3.40
est: 3.46 (-198.3%)
|
-3.05
est: 1.37 (-323.0%)
|
0.95
est: 1.20 (-20.9%)
|
-1.04
est: 5.01 (-120.8%)
|
3.50
est: 7.54 (-53.6%)
|
9.35
9.13 – 9.44
+24.1% YoY
|
10.76
10.19 – 11.73
+15.1% YoY
|
12.79
12.26 – 13.41
+18.9% YoY
|
13.65
13.08 – 14.31
+6.7% YoY
|
15.21
14.57 – 15.94
+11.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-04 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-01 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
194.69M
OE per share TTM
9.32
Owner's Yield
11.83%
Maintenance CapEx ratio
4.66%
Maint CapEx / Avg PPE
11.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
110
Total invested
400.63M
Insider transactions (90d)
0
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Meridian Venture Partners II GP, L.P. (“GP”) | 2.82M | 29.70% | — | 2.82M | — | 10.00 | PN | Delaware, United States of America | 2013-11-25 | ↗ |
| 2 | Meridian Venture Partners II, Co. (“MVP Corp.”) | 2.82M | 29.70% | — | 2.82M | — | 10.00 | CO | Delaware | 2013-11-25 | ↗ |
| 3 | Meridian Venture Partners II, L.P. (“MVP II”), | 2.82M | 29.70% | — | 2.82M | — | 10.00 | PN | Delaware | 2013-11-25 | ↗ |
| 4 | Robert E. Brown, Jr. | 2.82M | 29.70% | — | 2.82M | — | 10.00 | IN | United States of America | 2013-11-25 | ↗ |
| 5 | Thomas A. Penn | 2.82M | 29.70% | — | 2.82M | — | 10.00 | IN | United States of America | 2013-11-25 | ↗ |
| 6 | (1) BlackRock, Inc. | 1.69M | 11.80% | 1.66M | — | 1.69M | — | HC | Delaware | 2022-02-07 | ↗ |
| 7 | Muthusamy Shanmugam | 1.35M | 8.04% | 1.35M | — | 1.35M | — | IN | United States | 2022-03-02 | ↗ |
| 8 | Esjay LLC | 1.33M | 7.96% | 1.33M | — | 1.33M | — | OO | Delaware | 2022-03-02 | ↗ |
| 9 | The Vanguard Group - 23-1945930 | 1.29M | 6.31% | — | 23.6K | — | 38.1K | IA | Pennsylvania | 2024-02-13 | ↗ |
| 10 | David Rosen | 1.13M | 5.51% | — | 1.13M | — | — | IN | United States of America | 2024-02-12 | ↗ |
| 11 | LP | 1.13M | 5.51% | — | 1.13M | — | — | IA, PN | State of Delaware | 2024-02-12 | ↗ |
| 12 | ###-##-#### | 816.8K | 8.60% | 8.3K | 808.4K | — | — | IN | DE | 2014-02-13 | ↗ |
| 13 | 36-4432547 | 552.5K | 5.80% | 552.5K | — | 552.5K | — | PN | DE | 2014-02-13 | ↗ |
| 14 | Consonance Capman GP LLC | 491.6K | 4.25% | — | 491.6K | — | — | HC, OO | Delaware USA | 2017-02-13 | ↗ |
| 15 | Mitchell Blutt | 491.6K | 4.25% | — | 491.6K | — | — | HC, IN | USA | 2017-02-13 | ↗ |
| 16 | Consonance Capital Management LP | 480.4K | 4.15% | — | 480.4K | — | — | IA, PN | Delaware USA | 2017-02-13 | ↗ |
| 17 | 45-6899967 | 224.3K | 2.40% | 224.3K | — | 224.3K | — | OO | DE | 2014-02-13 | ↗ |
| 18 | ALLIANZ GLOBAL INVESTORS U.S. HOLDINGS LLC | 73.4K | 0.60% | — | — | — | — | HC, OO | Delaware | 2018-02-15 | ↗ |
| 19 | ALLIANZ GLOBAL INVESTORS U.S. LLC | 72.7K | 0.60% | 59.8K | — | 72.7K | — | IA, OO | Delaware | 2018-02-15 | ↗ |
| 20 | Foreign | 23.0K | 0.20% | 23.0K | — | 23.0K | — | PN | DE | 2014-02-13 | ↗ |
| 21 | Deerfield Management Company, L.P. | 13.2K | 0.12% | — | 13.2K | — | — | PN | Delaware | 2015-02-17 | ↗ |
| 22 | Deerfield Mgmt, L.P. | 13.2K | 0.12% | — | 13.2K | — | — | PN | Delaware | 2015-02-17 | ↗ |
| 23 | James E. Flynn | 13.2K | 0.12% | — | 13.2K | — | — | IN | United States | 2015-02-17 | ↗ |
| 24 | Consonance Capital Opportunity Fund Management LP | 11.2K | 0.10% | — | 11.2K | — | — | IA, PN | Delaware USA | 2017-02-13 | ↗ |
| 25 | Deerfield Special Situations Fund, L.P. | 8.5K | 0.07% | — | 8.5K | — | — | PN | Delaware | 2015-02-17 | ↗ |
| 26 | Deerfield Special Situations International Master Fund, L.P. | 4.8K | 0.04% | — | 4.8K | — | — | PN | British Virgin Islands | 2015-02-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
110
-182 vs prev Q
New positions
24
Closed positions
199
Increased
61
Reduced
26
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 299.3K +299.3K (+100.0%) | 23.63B +23.6B (+100.0%) | 1.49% +1.491 pp | 0.04% +0.036 pp | USD78.94 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 2.66M +112.8K (+4.4%) | 210.12M -23.4M (-10.0%) | 13.26% +0.408 pp | 0.00% -0.001 pp | USD60.40 +30.7% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 1.31M +27.6K (+2.2%) | 103.02M -14.0M (-12.0%) | 6.50% +0.061 pp | 0.00% 0.000 pp | USD49.84 +58.4% | 50 qtrs — |
| 4 | STATE STREET CORP | 727.2K +15.5K (+2.2%) | 57.41M -7.8M (-11.9%) | 3.62% +0.034 pp | 0.00% 0.000 pp | USD54.61 +44.6% | 51 qtrs — |
| 5 | GLOBAL ALPHA CAPITAL MANAGEMENT LTD. | 590.1K -40.5K (-6.4%) | 46.59M -11.2M (-19.3%) | 2.94% -0.240 pp | 2.84% -0.460 pp | USD53.84 +46.6% | 18 qtrs — |
| 6 | MILLENNIUM MANAGEMENT LLC | 539.7K +474.4K (+727.1%) | 42.60M +36.6M (+612.8%) | 2.69% +2.359 pp | 0.02% +0.015 pp | USD76.60 +3.1% | 18 qtrs — |
| 7 | DIMENSIONAL FUND ADVISORS LP | 487.7K -17.8K (-3.5%) | 38.50M -7.8M (-16.8%) | 2.43% -0.119 pp | 0.01% -0.002 pp | USD48.50 +62.8% | 50 qtrs — |
| 8 | SOLEUS CAPITAL MANAGEMENT, L.P. | 486.2K +146.0K (+42.9%) | 38.38M +7.2M (+23.2%) | 2.42% +0.707 pp | 1.42% -0.153 pp | USD84.53 -6.6% | 6 qtrs — |
| 9 | TANG CAPITAL MANAGEMENT LLC | 481.4K +163.9K (+51.6%) | 38.00M +8.9M (+30.7%) | 2.40% +0.798 pp | 1.88% +0.758 pp | USD69.69 +13.3% | 8 qtrs — |
| 10 | DEEP TRACK CAPITAL, LP | 477.7K +27.7K (+6.2%) | 37.71M -3.5M (-8.5%) | 2.38% +0.111 pp | 0.67% -0.478 pp | USD59.35 +33.0% | 11 qtrs — |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 477.3K +19.3K (+4.2%) | 37.68M -4.3M (-10.2%) | 2.38% +0.068 pp | 0.00% 0.000 pp | USD53.80 +46.7% | 50 qtrs — |
| 12 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 473.2K +113.0K (+31.4%) | 37.35M +4.4M (+13.2%) | 2.36% +0.541 pp | 0.02% +0.001 pp | USD88.58 -10.9% | 2 qtrs — |
| 13 | GOLDMAN SACHS GROUP INC | 400.3K +21.3K (+5.6%) | 31.60M -3.1M (-9.0%) | 1.99% +0.083 pp | 0.00% 0.000 pp | USD74.02 +6.6% | 44 qtrs — |
| 14 | DEUTSCHE BANK AG\ | 392.6K +140.0K (+55.4%) | 30.99M +7.9M (+34.0%) | 1.96% +0.682 pp | 0.01% +0.002 pp | USD68.98 +14.4% | 48 qtrs — |
| 15 | NUVEEN, LLC | 387.1K -8.0K (-2.0%) | 30.56M -5.6M (-15.6%) | 1.93% -0.064 pp | 0.01% -0.002 pp | USD67.07 +17.7% | 4 qtrs — |
| 16 | RANGER INVESTMENT MANAGEMENT, L.P. | 362.4K +91.0K (+33.5%) | 28.61M +3.8M (+15.1%) | 1.81% +0.437 pp | 1.96% +0.229 pp | USD59.82 +32.0% | 36 qtrs — |
| 17 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 316.7K -32.0K (-9.2%) | 25.00M -6.9M (-21.7%) | 1.58% -0.180 pp | 0.07% -0.013 pp | USD37.12 +112.7% | 19 qtrs — |
| 18 | RENAISSANCE TECHNOLOGIES LLC | 314.4K +41.5K (+15.2%) | 24.82M -178.9K (-0.7%) | 1.57% +0.190 pp | 0.04% +0.006 pp | USD77.38 +2.0% | 11 qtrs — |
| 19 | MORGAN STANLEY | 281.4K +49.4K (+21.3%) | 22.22M +962.2K (+4.5%) | 1.40% +0.232 pp | 0.00% +0.000 pp | USD66.20 +19.2% | 49 qtrs — |
| 20 | AMERIPRISE FINANCIAL INC | 269.9K -21.9K (-7.5%) | 21.31M -5.4M (-20.3%) | 1.34% -0.127 pp | 0.00% -0.001 pp | USD46.95 +68.1% | 47 qtrs — |
| 21 | D. E. SHAW & CO., INC. | 253.5K +40.5K (+19.0%) | 20.01M +502.8K (+2.6%) | 1.26% +0.189 pp | 0.01% +0.000 pp | USD80.85 -2.4% | 7 qtrs — |
| 22 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 251.6K +16.0K (+6.8%) | 19.86M -1.7M (-8.0%) | 1.25% +0.065 pp | 0.00% 0.000 pp | USD61.23 +28.9% | 47 qtrs — |
| 23 | JPMORGAN CHASE & CO | 244.7K +115.6K (+89.5%) | 19.31M +7.5M (+63.3%) | 1.22% +0.568 pp | 0.00% +0.001 pp | USD69.13 +14.2% | 40 qtrs — |
| 24 | ABRDN PLC | 240.8K -28.9K (-10.7%) | 19.01M -5.7M (-23.1%) | 1.20% -0.160 pp | 0.03% -0.010 pp | USD60.32 +30.9% | 5 qtrs — |
| 25 | NOMURA HOLDINGS INC | 223.9K +28.4K (+14.5%) | 17.68M -232.0K (-1.3%) | 1.12% +0.130 pp | 0.02% -0.004 pp | USD83.77 -5.8% | 6 qtrs — |
| 26 | ROYAL BANK OF CANADA | 221.3K +10.6K (+5.0%) | 17.47M -1.8M (-9.5%) | 1.10% +0.040 pp | 0.00% 0.000 pp | USD60.50 +30.5% | 50 qtrs — |
| 27 | BANK OF MONTREAL /CAN/ | 219.4K +25.1K (+12.9%) | 17.32M -477.1K (-2.7%) | 1.09% +0.113 pp | 0.01% -0.001 pp | USD61.73 +27.9% | 6 qtrs — |
| 28 | QUBE RESEARCH & TECHNOLOGIES LTD | 217.9K +27.7K (+14.6%) | 17.20M -222.9K (-1.3%) | 1.09% +0.126 pp | 0.02% -0.001 pp | USD79.80 -1.1% | 10 qtrs — |
| 29 | KENNEDY CAPITAL MANAGEMENT LLC | 213.8K +23.4K (+12.3%) | 16.88M -562.0K (-3.2%) | 1.07% +0.105 pp | 0.36% -0.028 pp | USD49.46 +59.6% | 15 qtrs — |
| 30 | BALYASNY ASSET MANAGEMENT L.P. | 205.1K -81.1K (-28.3%) | 16.19M -10.0M (-38.2%) | 1.02% -0.421 pp | 0.02% -0.013 pp | USD90.69 -13.0% | 9 qtrs — |
| 31 | MIZUHO MARKETS AMERICAS LLC | 202.0K +21.4K (+11.9%) | 15.95M -595.5K (-3.6%) | 1.01% +0.096 pp | 0.31% -0.003 pp | USD61.97 +27.4% | 6 qtrs — |
| 32 | CAPTION MANAGEMENT, LLC | 200.0K +200.0K (+100.0%) | 15.79M +15.8M (+100.0%) | 1.00% +0.996 pp | 0.11% +0.108 pp | USD78.94 +0.0% | 1 qtrs NEW |
| 33 | APIS CAPITAL ADVISORS, LLC | 196.0K +32.0K (+19.5%) | 15.47M +449.8K (+3.0%) | 0.98% +0.150 pp | 2.70% -0.622 pp | USD72.89 +8.3% | 4 qtrs — |
| 34 | BNP PARIBAS ARBITRAGE, SNC | 193.6K -34.0K (-14.9%) | 15.28M -5.6M (-26.7%) | 0.96% -0.183 pp | 0.01% -0.004 pp | USD87.10 -9.4% | 46 qtrs — |
| 35 | SCHONFELD STRATEGIC ADVISORS LLC | 192.0K +170.2K (+780.8%) | 15.16M +13.2M (+659.0%) | 0.96% +0.847 pp | 0.07% +0.056 pp | USD77.58 +1.8% | 4 qtrs — |
| 36 | INVESCO LTD. | 189.8K +39.2K (+26.0%) | 14.99M +1.2M (+8.6%) | 0.95% +0.186 pp | 0.00% +0.000 pp | USD63.66 +24.0% | 47 qtrs — |
| 37 | OBERWEIS ASSET MANAGEMENT INC/ | 188.8K +49.9K (+35.9%) | 14.91M +2.2M (+17.2%) | 0.94% +0.240 pp | 0.55% +0.058 pp | USD65.88 +19.8% | 10 qtrs — |
| 38 | TWO SIGMA INVESTMENTS, LP | 181.2K +127.4K (+236.8%) | 14.30M +9.4M (+190.3%) | 0.90% +0.631 pp | 0.02% +0.013 pp | USD82.70 -4.5% | 11 qtrs — |
| 39 | NORTHERN TRUST CORP | 176.8K -11.8K (-6.2%) | 13.96M -3.3M (-19.2%) | 0.88% -0.070 pp | 0.00% 0.000 pp | USD47.45 +66.4% | 49 qtrs — |
| 40 | CITIGROUP INC | 172.0K +68.0K (+65.4%) | 13.58M +4.1M (+42.5%) | 0.86% +0.332 pp | 0.01% +0.002 pp | USD82.48 -4.3% | 47 qtrs — |
| 41 | LOOMIS SAYLES & CO L P | 168.8K -3.3K (-1.9%) | 13.33M -2.4M (-15.5%) | 0.84% -0.027 pp | 0.02% -0.003 pp | USD48.11 +64.1% | 12 qtrs — |
| 42 | TEACHER RETIREMENT SYSTEM OF TEXAS | 151.3K -1.6K (-1.1%) | 11.94M -2.1M (-14.7%) | 0.75% -0.017 pp | 0.04% -0.015 pp | USD66.19 +19.3% | 11 qtrs — |
| 43 | UBS GROUP AG | 150.8K -439.1K (-74.4%) | 11.90M -42.1M (-78.0%) | 0.75% -2.223 pp | 0.00% -0.007 pp | USD69.95 +12.9% | 45 qtrs — |
| 44 | PARKMAN HEALTHCARE PARTNERS LLC | 145.0K +145.0K (+100.0%) | 11.45M +11.4M (+100.0%) | 0.72% +0.722 pp | 1.09% +1.090 pp | USD78.94 +0.0% | 4 qtrs — |
| 45 | FREESTONE GROVE PARTNERS LP | 141.1K +110.4K (+359.9%) | 11.14M +8.3M (+296.3%) | 0.70% +0.548 pp | 0.08% +0.060 pp | USD75.92 +4.0% | 5 qtrs — |
| 46 | PENN CAPITAL MANAGEMENT COMPANY, LLC | 137.4K +131.0K (+2,058.9%) | 10.86M +10.3M (+1,762.6%) | 0.68% +0.652 pp | 0.87% +0.821 pp | USD78.45 +0.6% | 4 qtrs — |
| 47 | RUSSELL INVESTMENTS GROUP, LTD. | 126.5K +32.4K (+34.4%) | 9.98M +1.4M (+15.8%) | 0.63% +0.156 pp | 0.01% +0.001 pp | USD61.94 +27.4% | 26 qtrs — |
| 48 | POINT72 ASSET MANAGEMENT, L.P. | 121.2K -277.9K (-69.6%) | 9.57M -27.0M (-73.8%) | 0.60% -1.408 pp | 0.01% -0.051 pp | USD91.60 -13.8% | 2 qtrs — |
| 49 | WALLEYE CAPITAL LLC | 117.3K -99.0K (-45.8%) | 9.26M -10.6M (-53.3%) | 0.58% -0.506 pp | 0.03% -0.046 pp | USD85.98 -8.2% | 7 qtrs — |
| 50 | BANK OF NEW YORK MELLON CORP | 112.6K -3.6K (-3.1%) | 8.89M -1.8M (-16.5%) | 0.56% -0.025 pp | 0.00% -0.001 pp | USD54.18 +45.7% | 47 qtrs — |
| 51 | PRINCIPAL FINANCIAL GROUP INC | 108.5K +10.0K (+10.1%) | 8.56M -459.1K (-5.1%) | 0.54% +0.044 pp | 0.00% 0.000 pp | USD62.00 +27.3% | 44 qtrs — |
| 52 | JANE STREET GROUP, LLC | 100.7K +95.2K (+1,730.9%) | 7.95M +7.4M (+1,477.9%) | 0.50% +0.474 pp | 0.00% +0.001 pp | USD79.63 -0.9% | 2 qtrs — |
| 53 | THOMPSON SIEGEL & WALMSLEY LLC | 100.1K +8.6K (+9.4%) | 7.90M -476.0K (-5.7%) | 0.50% +0.038 pp | 0.13% -0.003 pp | USD43.50 +81.5% | 24 qtrs — |
| 54 | NEW YORK STATE COMMON RETIREMENT FUND | 96.7K +90.0K (+1,325.7%) | 7.64M +7.0M (+1,128.7%) | 0.48% +0.448 pp | 0.01% +0.009 pp | USD77.45 +1.9% | 44 qtrs — |
| 55 | SG AMERICAS SECURITIES, LLC | 96.2K +73.3K (+321.0%) | 7.59M +5.5M (+262.8%) | 0.48% +0.364 pp | 0.01% +0.003 pp | USD81.24 -2.8% | 8 qtrs — |
| 56 | ASSENAGON ASSET MANAGEMENT S.A. | 89.8K +43.4K (+93.8%) | 7.09M +2.8M (+67.0%) | 0.45% +0.214 pp | 0.01% +0.004 pp | USD80.76 -2.3% | 10 qtrs — |
| 57 | FIRST TRUST ADVISORS LP | 88.4K +19.0K (+27.4%) | 6.98M +622.3K (+9.8%) | 0.44% +0.091 pp | 0.01% +0.000 pp | USD67.68 +16.6% | 7 qtrs — |
| 58 | SIO CAPITAL MANAGEMENT, LLC | 87.3K +31.5K (+56.6%) | 6.89M +1.8M (+35.0%) | 0.43% +0.154 pp | 1.08% -0.208 pp | USD65.28 +20.9% | 8 qtrs — |
| 59 | IKARIAN CAPITAL, LLC | 82.8K +82.8K (+100.0%) | 6.54M +6.5M (+100.0%) | 0.41% +0.413 pp | 0.51% +0.510 pp | USD78.94 +0.0% | 1 qtrs NEW |
| 60 | BARCLAYS PLC | 81.8K -61.2K (-42.8%) | 6.46M -2.1M (-24.3%) | 0.41% -0.314 pp | 0.00% -0.001 pp | USD60.44 +30.6% | 50 qtrs — |
| 61 | VICTORY CAPITAL MANAGEMENT INC | 81.1K +17.0K (+26.5%) | 6.40M +527.6K (+9.0%) | 0.40% +0.081 pp | 0.00% +0.000 pp | USD67.78 +16.5% | 8 qtrs — |
| 62 | RAYMOND JAMES FINANCIAL INC | 80.9K -6.2K (-7.2%) | 6.39M -1.6M (-19.9%) | 0.40% -0.036 pp | 0.00% -0.001 pp | USD58.70 +34.5% | 5 qtrs — |
| 63 | MAN GROUP PLC | 80.7K +45.9K (+132.1%) | 6.37M +3.2M (+100.0%) | 0.40% +0.227 pp | 0.01% +0.005 pp | USD73.70 +7.1% | 3 qtrs — |
| 64 | PACER ADVISORS, INC. | 79.9K +75.8K (+1,821.1%) | 6.31M +5.9M (+1,555.6%) | 0.40% +0.377 pp | 0.02% +0.015 pp | USD79.60 -0.8% | 2 qtrs — |
| 65 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 78.6K -50.1K (-39.0%) | 6.20M -5.6M (-47.4%) | 0.39% -0.258 pp | 0.02% -0.021 pp | USD77.17 +2.3% | 10 qtrs — |
| 66 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 77.7K +10.3K (+15.3%) | 6.13M -38.4K (-0.6%) | 0.39% +0.047 pp | 0.02% -0.002 pp | USD63.60 +24.1% | 44 qtrs — |
| 67 | DRIEHAUS CAPITAL MANAGEMENT LLC | 76.2K -2.6K (-3.3%) | 6.01M -1.2M (-16.7%) | 0.38% -0.018 pp | 0.04% -0.011 pp | USD91.60 -13.8% | 2 qtrs — |
| 68 | HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | 74.8K +320.0 (+0.4%) | 5.90M -917.4K (-13.5%) | 0.37% -0.003 pp | 0.02% -0.003 pp | USD62.97 +25.4% | 6 qtrs — |
| 69 | MARATHON CAPITAL MANAGEMENT | 69.7K -40.0 (-0.1%) | 5.50M -885.6K (-13.9%) | 0.35% -0.004 pp | 1.18% -0.278 pp | USD36.68 +115.2% | 18 qtrs — |
| 70 | F/M INVESTMENTS LLC | 67.8K +11.8K (+21.0%) | 5.35M +218.2K (+4.2%) | 0.34% +0.055 pp | 0.20% +0.005 pp | USD63.09 +25.1% | 6 qtrs — |
| 71 | TREXQUANT INVESTMENT LP | 67.4K +12.5K (+22.8%) | 5.32M +292.9K (+5.8%) | 0.34% +0.059 pp | 0.05% -0.004 pp | USD70.16 +12.5% | 3 qtrs — |
| 72 | AMUNDI | 65.7K +41.8K (+174.8%) | 5.19M +3.0M (+135.6%) | 0.33% +0.207 pp | 0.00% +0.001 pp | USD74.07 +6.6% | 3 qtrs — |
| 73 | GREAT LAKES ADVISORS, LLC | 59.6K +— (+0.0%) | 4.71M -755.0K (-13.8%) | 0.30% -0.004 pp | 0.04% -0.007 pp | USD52.76 +49.6% | 12 qtrs — |
| 74 | AMERICAN CENTURY COMPANIES INC | 58.2K +27.0K (+86.3%) | 4.60M +1.7M (+60.6%) | 0.29% +0.133 pp | 0.00% +0.001 pp | USD76.41 +3.3% | 11 qtrs — |
| 75 | GLOBEFLEX CAPITAL L P | 55.4K +24.8K (+80.9%) | 4.37M +1.6M (+55.9%) | 0.28% +0.122 pp | 0.67% +0.237 pp | USD79.10 -0.2% | 11 qtrs — |
| 76 | DIADEMA PARTNERS LP | 53.4K +22.0K (+69.9%) | 4.21M +1.3M (+46.4%) | 0.27% +0.108 pp | 0.73% -0.010 pp | USD86.39 -8.6% | 2 qtrs — |
| 77 | SQUAREPOINT OPS LLC | 49.5K -24.2K (-32.8%) | 3.91M -2.8M (-42.1%) | 0.25% -0.125 pp | 0.00% -0.003 pp | USD79.88 -1.2% | 3 qtrs — |
| 78 | BROWN ADVISORY INC | 48.4K +33.3K (+221.0%) | 3.82M +2.4M (+176.7%) | 0.24% +0.165 pp | 0.01% +0.004 pp | USD70.58 +11.8% | 28 qtrs — |
| 79 | OSSIAM | 47.4K +— (+0.0%) | 3.74M -600.1K (-13.8%) | 0.24% -0.003 pp | 0.07% +0.019 pp | USD91.60 -13.8% | 2 qtrs — |
| 80 | BANK OF AMERICA CORP /DE/ | 45.7K -85.0K (-65.0%) | 3.61M -8.4M (-69.9%) | 0.23% -0.432 pp | 0.00% -0.001 pp | USD61.07 +29.3% | 50 qtrs — |
| 81 | PDT PARTNERS, LLC | 45.4K +— (+0.0%) | 3.59M -575.3K (-13.8%) | 0.23% -0.003 pp | 0.23% -0.030 pp | USD65.25 +21.0% | 3 qtrs — |
| 82 | Y-INTERCEPT (HONG KONG) LTD | 45.4K +37.7K (+490.5%) | 3.58M +2.9M (+408.8%) | 0.23% +0.187 pp | 0.08% +0.063 pp | USD81.08 -2.6% | 2 qtrs — |
| 83 | LEGAL & GENERAL GROUP PLC | 44.3K +164.0 (+0.4%) | 3.50M -545.6K (-13.5%) | 0.22% -0.002 pp | 0.00% 0.000 pp | USD53.86 +46.6% | 45 qtrs — |
| 84 | PRUDENTIAL FINANCIAL INC | 42.4K -7.3K (-14.7%) | 3.35M -1.2M (-26.5%) | 0.21% -0.040 pp | 0.00% -0.001 pp | USD77.86 +1.4% | 44 qtrs — |
| 85 | SEI INVESTMENTS CO | 41.8K +18.4K (+78.5%) | 3.30M +1.2M (+53.9%) | 0.21% +0.090 pp | 0.00% +0.001 pp | USD79.13 -0.2% | 13 qtrs — |
| 86 | RHUMBLINE ADVISERS | 40.4K -2.1K (-4.9%) | 3.19M -701.1K (-18.0%) | 0.20% -0.013 pp | 0.00% -0.001 pp | USD52.92 +49.2% | 45 qtrs — |
| 87 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 39.4K +221.0 (+0.6%) | 3.11M -478.4K (-13.3%) | 0.20% -0.001 pp | 0.01% -0.002 pp | USD58.94 +33.9% | 18 qtrs — |
| 88 | INTECH INVESTMENT MANAGEMENT LLC | 38.5K +11.0K (+39.9%) | 3.04M +517.8K (+20.5%) | 0.19% +0.053 pp | 0.03% +0.005 pp | USD67.53 +16.9% | 6 qtrs — |
| 89 | BESSEMER GROUP INC | 38.1K +37.9K (+20,954.7%) | 3.01M +3.0M (+17,600.0%) | 0.19% +0.189 pp | 0.00% +0.005 pp | USD78.91 +0.0% | 8 qtrs — |
| 90 | CAXTON ASSOCIATES LLP | 37.8K +— (+0.0%) | 2.99M -479.2K (-13.8%) | 0.19% -0.002 pp | 0.06% -0.023 pp | USD91.60 -13.8% | 2 qtrs — |
| 91 | SEGALL BRYANT & HAMILL, LLC | 36.4K -668.0 (-1.8%) | 2.87M -521.4K (-15.4%) | 0.18% -0.006 pp | 0.04% -0.006 pp | USD63.38 +24.6% | 7 qtrs — |
| 92 | ALGERT GLOBAL LLC | 35.9K +30.7K (+586.6%) | 2.84M +2.4M (+491.9%) | 0.18% +0.153 pp | 0.04% +0.036 pp | USD80.78 -2.3% | 2 qtrs — |
| 93 | SWISS NATIONAL BANK | 35.1K +1.6K (+4.8%) | 2.77M -297.8K (-9.7%) | 0.17% +0.006 pp | 0.00% 0.000 pp | USD51.75 +52.5% | 43 qtrs — |
| 94 | GOTHAM ASSET MANAGEMENT, LLC | 32.8K +24.3K (+282.4%) | 2.59M +1.8M (+229.6%) | 0.16% +0.120 pp | 0.01% +0.006 pp | USD82.25 -4.0% | 2 qtrs — |
| 95 | HUSSMAN STRATEGIC ADVISORS, INC. | 31.5K +31.5K (+100.0%) | 2.49M +2.5M (+100.0%) | 0.16% +0.157 pp | 0.60% +0.601 pp | USD78.94 +0.0% | 1 qtrs NEW |
| 96 | UBS ASSET MANAGEMENT AMERICAS INC | 30.9K +1.2K (+4.0%) | 2.44M -280.8K (-10.3%) | 0.15% +0.004 pp | 0.00% 0.000 pp | USD58.36 +35.3% | 20 qtrs — |
| 97 | LISANTI CAPITAL GROWTH, LLC | 30.4K -52.2K (-63.2%) | 2.40M -5.2M (-68.3%) | 0.15% -0.265 pp | 0.57% -1.282 pp | USD65.52 +20.5% | 8 qtrs — |
| 98 | WELLS FARGO & COMPANY/MN | 29.6K +11.4K (+62.4%) | 2.34M +668.4K (+40.0%) | 0.15% +0.056 pp | 0.00% +0.000 pp | USD69.92 +12.9% | 48 qtrs — |
| 99 | CAMPBELL & CO INVESTMENT ADVISER LLC | 28.8K +11.4K (+65.2%) | 2.27M +676.5K (+42.3%) | 0.14% +0.056 pp | 0.11% -0.012 pp | USD86.60 -8.8% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 145 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco Pharmaceuticals ETF PJP | 2.70% | 9.65M | 0.57% |
| 2 | abrdn Focused U.S. Small Cap Active ETF AFSC | 2.26% | 226.7K | 1.09% |
| 3 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.48% | 6.99M | 0.35% |
| 4 | Invesco S&P SmallCap 600 Revenue ETF RZG | 1.03% | 1.48M | 0.35% |
| 5 | Invesco S&P SmallCap Health Care ETF PSCH | 0.65% | 1.07M | 0.29% |
| 6 | Pacer US Small Cap Cash Cows Growth Leaders ETF CAFG | 0.59% | 176.7K | 0.59% |
| 7 | Janus Henderson Small/Mid Cap Growth Alpha ETF JSMD | 0.54% | 5.85M | 0.30% |
| 8 | VictoryShares Small Cap Free Cash Flow ETF SFLO | 0.48% | 3.04M | 0.56% |
| 9 | Acuitas Small Cap Active ETF AIMS | 0.46% | 340.8K | 0.75% |
| 10 | ETC 6 Meridian Low Beta Equity ETF SIXL | 0.46% | 846.5K | 0.47% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
500.00
Cash buys
—
Cash sales
1.00
Net activity
-500
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 500 | 77.95 | 39.0K | 78,890 | D | ↗ |
| 2026-03-13 | Mutz Christopher | Officer | S-Sale | D | Common Stock | 3,162 | 71.64 | 226.5K | 91,309 | D | ↗ |
| 2026-03-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 500 | 72.62 | 36.3K | 79,390 | D | ↗ |
| 2026-03-11 | Rowland Thomas Andrew | Officer | S-Sale | D | Common Stock | 4,772 | 74.91 | 357.5K | 38,730 | D | ↗ |
| 2026-03-09 | Mutz Christopher | Officer | S-Sale | D | Common Stock | 3,602 | 74.18 | 267.2K | 94,471 | D | ↗ |
| 2026-03-09 | Davis Krista | Officer | S-Sale | D | Common Stock | 5,087 | 74.13 | 377.1K | 51,946 | D | ↗ |
| 2026-03-07 | Mutz Christopher | Officer | F-InKind | D | Common Stock | 3,314 | 74.04 | 245.4K | 98,073 | D | ↗ |
| 2026-03-07 | Lalwani Nikhil | Director / Officer | F-InKind | D | Common Stock | 17,060 | 74.04 | 1.26M | 404,889 | D | ↗ |
| 2026-03-07 | Gutwerg Ori | Officer | F-InKind | D | Common Stock | 3,314 | 74.04 | 245.4K | 81,468 | D | ↗ |
| 2026-03-07 | CAREY STEPHEN P. | Officer | F-InKind | D | Common Stock | 5,150 | 74.04 | 381.3K | 180,393 | D | ↗ |
| 2026-03-06 | Mutz Christopher | Officer | S-Sale | D | Common Stock | 2,121 | 74.22 | 157.4K | 101,387 | D | ↗ |
| 2026-03-06 | Davis Krista | Officer | S-Sale | D | Common Stock | 1,485 | 75.00 | 111.4K | 57,033 | D | ↗ |
| 2026-03-05 | CAREY STEPHEN P. | Officer | M-Exempt | A | Common Stock | 3,312 | 49.51 | 164.0K | 192,855 | D | ↗ |
| 2026-03-03 | Walsh Patrick D | Director | S-Sale | D | Common Stock | 6,000 | 74.23 | 445.4K | 52,405 | D | ↗ |
| 2026-03-03 | Gutwerg Ori | Officer | S-Sale | D | Common Stock | 2,060 | 76.50 | 157.6K | 84,782 | D | ↗ |
| 2026-03-02 | Mutz Christopher | Officer | S-Sale | D | Common Stock | 417 | 74.00 | 30.9K | 103,508 | D | ↗ |
| 2026-02-28 | Rowland Thomas Andrew | Officer | F-InKind | D | Common Stock | 628 | 73.90 | 46.4K | 43,502 | D | ↗ |
| 2026-02-28 | Mutz Christopher | Officer | F-InKind | D | Common Stock | 2,221 | 73.90 | 164.1K | 103,925 | D | ↗ |
| 2026-02-28 | Lalwani Nikhil | Director / Officer | F-InKind | D | Common Stock | 12,217 | 73.90 | 902.8K | 421,949 | D | ↗ |
| 2026-02-28 | Gutwerg Ori | Officer | F-InKind | D | Common Stock | 2,221 | 73.90 | 164.1K | 86,842 | D | ↗ |
| 2026-02-28 | Gassert Chad | Officer | F-InKind | D | Common Stock | 2,221 | 73.90 | 164.1K | 74,916 | D | ↗ |
| 2026-02-28 | Davis Krista | Officer | F-InKind | D | Common Stock | 1,555 | 73.90 | 114.9K | 58,518 | D | ↗ |
| 2026-02-28 | Cook Meredith | Officer | F-InKind | D | Common Stock | 1,555 | 73.90 | 114.9K | 79,890 | D | ↗ |
| 2026-02-28 | CAREY STEPHEN P. | Officer | F-InKind | D | Common Stock | 2,773 | 73.90 | 204.9K | 189,543 | D | ↗ |
| 2026-02-26 | Shanmugam Muthusamy | Director / Officer | A-Award | A | Common Stock | 11,116 | 77.15 | 857.6K | 101,056 | D | ↗ |
| 2026-02-26 | Rowland Thomas Andrew | Officer | A-Award | A | Common Stock | 6,021 | 77.15 | 464.5K | 44,130 | D | ↗ |
| 2026-02-26 | Mutz Christopher | Officer | A-Award | A | Common Stock | 21,306 | 77.15 | 1.64M | 106,146 | D | ↗ |
| 2026-02-26 | Lalwani Nikhil | Director / Officer | A-Award | A | Common Stock | 75,592 | 77.15 | 5.83M | 434,166 | D | ↗ |
| 2026-02-26 | Gutwerg Ori | Officer | A-Award | A | Common Stock | 12,969 | 77.15 | 1.00M | 89,063 | D | ↗ |
| 2026-02-26 | Gassert Chad | Officer | A-Award | A | Common Stock | 11,116 | 77.15 | 857.6K | 77,137 | D | ↗ |
| 2026-02-26 | Davis Krista | Officer | A-Award | A | Common Stock | 10,810 | 77.15 | 834.0K | 60,073 | D | ↗ |
| 2026-02-26 | Cook Meredith | Officer | A-Award | A | Common Stock | 13,895 | 77.15 | 1.07M | 81,445 | D | ↗ |
| 2026-02-26 | CAREY STEPHEN P. | Officer | A-Award | A | Common Stock | 22,233 | 77.15 | 1.72M | 192,316 | D | ↗ |
| 2026-02-20 | Mutz Christopher | Officer | S-Sale | D | Common Stock | 5,323 | 78.02 | 415.3K | 84,840 | D | ↗ |
| 2026-02-20 | Davis Krista | Officer | S-Sale | D | Common Stock | 1,730 | 77.99 | 134.9K | 49,263 | D | ↗ |
| 2026-02-19 | Davis Krista | Officer | S-Sale | D | Common Stock | 2,084 | 77.53 | 161.6K | 50,993 | D | ↗ |
| 2026-02-14 | Rowland Thomas Andrew | Officer | F-InKind | D | Common Stock | 485 | 77.36 | 37.5K | 38,109 | D | ↗ |
| 2026-02-14 | Mutz Christopher | Officer | F-InKind | D | Common Stock | 2,403 | 77.36 | 185.9K | 90,163 | D | ↗ |
| 2026-02-14 | Lalwani Nikhil | Director / Officer | F-InKind | D | Common Stock | 10,298 | 77.36 | 796.7K | 358,574 | D | ↗ |
| 2026-02-14 | Gutwerg Ori | Officer | F-InKind | D | Common Stock | 1,888 | 77.36 | 146.1K | 76,094 | D | ↗ |
| 2026-02-14 | Gassert Chad | Officer | F-InKind | D | Common Stock | 1,717 | 77.36 | 132.8K | 66,021 | D | ↗ |
| 2026-02-14 | Davis Krista | Officer | F-InKind | D | Common Stock | 1,290 | 77.36 | 99.8K | 53,077 | D | ↗ |
| 2026-02-14 | Cook Meredith | Officer | F-InKind | D | Common Stock | 1,779 | 77.36 | 137.6K | 67,550 | D | ↗ |
| 2026-02-14 | CAREY STEPHEN P. | Officer | F-InKind | D | Common Stock | 2,448 | 77.36 | 189.4K | 170,083 | D | ↗ |
| 2026-02-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 500 | 76.80 | 38.4K | 69,329 | D | ↗ |
| 2026-02-12 | Rowland Thomas Andrew | Officer | F-InKind | D | Common Stock | 566 | 76.70 | 43.4K | 38,594 | D | ↗ |
| 2026-02-12 | Mutz Christopher | Officer | S-Sale | D | Common Stock | 7,032 | 76.55 | 538.3K | 92,566 | D | ↗ |
| 2026-02-12 | Lalwani Nikhil | Director / Officer | F-InKind | D | Common Stock | 11,688 | 76.70 | 896.5K | 368,872 | D | ↗ |
| 2026-02-12 | Gutwerg Ori | Officer | F-InKind | D | Common Stock | 1,775 | 76.70 | 136.1K | 77,982 | D | ↗ |
| 2026-02-12 | Gassert Chad | Officer | F-InKind | D | Common Stock | 1,608 | 76.70 | 123.3K | 67,738 | D | ↗ |
| 2026-02-12 | Davis Krista | Officer | F-InKind | D | Common Stock | 1,180 | 76.70 | 90.5K | 54,367 | D | ↗ |
| 2026-02-12 | Cook Meredith | Officer | F-InKind | D | Common Stock | 1,534 | 76.70 | 117.7K | 69,829 | D | ↗ |
| 2026-02-12 | CAREY STEPHEN P. | Officer | F-InKind | D | Common Stock | 2,829 | 76.70 | 217.0K | 172,531 | D | ↗ |
| 2026-02-11 | Shanmugam Muthusamy | Director / Officer | F-InKind | D | Common Stock | 2,898 | 76.25 | 221.0K | 89,940 | D | ↗ |
| 2026-02-11 | Rowland Thomas Andrew | Officer | F-InKind | D | Common Stock | 1,762 | 76.25 | 134.4K | 39,160 | D | ↗ |
| 2026-02-11 | Mutz Christopher | Officer | F-InKind | D | Common Stock | 4,546 | 76.25 | 346.6K | 102,771 | D | ↗ |
| 2026-02-11 | Lalwani Nikhil | Director / Officer | F-InKind | D | Common Stock | 30,659 | 76.25 | 2.34M | 380,560 | D | ↗ |
| 2026-02-11 | Gutwerg Ori | Officer | F-InKind | D | Common Stock | 4,267 | 76.25 | 325.4K | 79,757 | D | ↗ |
| 2026-02-11 | Gassert Chad | Officer | F-InKind | D | Common Stock | 4,269 | 76.25 | 325.5K | 69,346 | D | ↗ |
| 2026-02-11 | Davis Krista | Officer | F-InKind | D | Common Stock | 3,017 | 76.25 | 230.0K | 55,547 | D | ↗ |
| 2026-02-11 | Cook Meredith | Officer | F-InKind | D | Common Stock | 3,011 | 76.25 | 229.6K | 71,363 | D | ↗ |
| 2026-02-11 | CAREY STEPHEN P. | Officer | F-InKind | D | Common Stock | 5,503 | 76.25 | 419.6K | 175,360 | D | ↗ |
| 2026-01-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 500 | 84.33 | 42.2K | 74,374 | D | ↗ |
| 2025-12-18 | Davis Krista | Officer | S-Sale | D | Common Stock | 1,622 | 82.40 | 133.7K | 58,564 | D | ↗ |
| 2025-12-12 | Cook Meredith | Officer | S-Sale | D | Common Stock | 400 | 82.32 | 32.9K | 74,874 | D | ↗ |
| 2025-12-05 | TANNENBAUM RENEE P | Director | S-Sale | D | Common Stock | 1,800 | 81.15 | 146.1K | 25,157 | D | ↗ |
| 2025-11-13 | Walsh Patrick D | Director | S-Sale | D | Common Stock | 8,643 | 86.88 | 750.9K | 61,405 | D | ↗ |
| 2025-11-13 | Gassert Chad | Officer | S-Sale | D | Common Stock | 94 | 88.00 | 8.3K | 158,490 | I | ↗ |
| 2025-11-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 400 | 87.27 | 34.9K | 75,274 | D | ↗ |
| 2025-11-12 | Gassert Chad | Officer | S-Sale | D | Common Stock | 14,642 | 89.07 | 1.30M | 158,584 | I | ↗ |
| 2025-10-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 400 | 90.09 | 36.0K | 75,674 | D | ↗ |
| 2025-09-19 | Davis Krista | Officer | S-Sale | D | Common Stock | 1,000 | 98.04 | 98.0K | 60,186 | D | ↗ |
| 2025-09-12 | Davis Krista | Officer | F-InKind | D | Common Stock | 1,710 | 97.71 | 167.1K | 61,186 | D | ↗ |
| 2025-09-12 | Cook Meredith | Officer | S-Sale | D | Common Stock | 400 | 98.42 | 39.4K | 76,074 | D | ↗ |
| 2025-09-03 | Pera Antonio R | Director | S-Sale | D | Common Stock | 7,292 | 94.94 | 692.3K | 22,660 | D | ↗ |
| 2025-08-25 | Leonard Matthew J | Director | S-Sale | D | Common Stock | 2,528 | 90.62 | 229.1K | 6,864 | D | ↗ |
| 2025-08-22 | Davis Krista | Officer | S-Sale | D | Common Stock | 1,763 | 91.10 | 160.6K | 62,896 | D | ↗ |
| 2025-08-21 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 52,988 | 90.44 | 4.79M | 431,920 | I | ↗ |
| 2025-08-20 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 47,012 | 90.27 | 4.24M | 484,908 | I | ↗ |
| 2025-08-20 | Pera Antonio R | Director | S-Sale | D | Common Stock | 5,421 | 89.73 | 486.4K | 29,952 | D | ↗ |
| 2025-08-18 | Thoma Jeanne | Director | S-Sale | D | Common Stock | 14,675 | 88.87 | 1.30M | 23,405 | D | ↗ |
| 2025-08-18 | Leonard Matthew J | Director | S-Sale | D | Common Stock | 6,937 | 88.17 | 611.6K | 9,392 | D | ↗ |
| 2025-08-15 | Walsh Patrick D | Director | S-Sale | D | Common Stock | 9,000 | 89.05 | 801.5K | 70,048 | D | ↗ |
| 2025-08-15 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 52,990 | 87.15 | 4.62M | 531,920 | I | ↗ |
| 2025-08-15 | Gassert Chad | Officer | S-Sale | D | Common Stock | 20,000 | 86.97 | 1.74M | 173,226 | I | ↗ |
| 2025-08-14 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 47,010 | 89.48 | 4.21M | 584,910 | I | ↗ |
| 2025-08-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 400 | 88.87 | 35.5K | 76,474 | D | ↗ |
| 2025-08-12 | Rowland Thomas Andrew | Officer | S-Sale | D | Common Stock | 4,975 | 85.71 | 426.4K | 40,794 | D | ↗ |
| 2025-08-12 | Lalwani Nikhil | Director / Officer | S-Sale | D | Common Stock | 56,960 | 85.93 | 4.89M | 411,219 | D | ↗ |
| 2025-08-12 | HAUGHEY THOMAS | Director | S-Sale | D | Common Stock | 19,341 | 85.93 | 1.66M | 36,521 | D | ↗ |
| 2025-08-12 | Gutwerg Ori | Officer | S-Sale | D | Common Stock | 5,873 | 86.53 | 508.2K | 84,024 | D | ↗ |
| 2025-08-12 | CAREY STEPHEN P. | Officer | S-Sale | D | Common Stock | 50,000 | 86.07 | 4.30M | 180,863 | D | ↗ |
| 2025-07-18 | Cook Meredith | Officer | F-InKind | D | Common Stock | 2,071 | 66.30 | 137.3K | 76,874 | D | ↗ |
| 2025-07-14 | Cook Meredith | Officer | S-Sale | D | Common Stock | 400 | 64.88 | 26.0K | 78,945 | D | ↗ |
| 2025-06-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 400 | 61.37 | 24.5K | 79,345 | D | ↗ |
| 2025-05-22 | Walsh Patrick D | Director | A-Award | A | Common Stock | 4,336 | 0.00 | — | 79,048 | D | ↗ |
| 2025-05-22 | Thoma Jeanne | Director | A-Award | A | Common Stock | 4,336 | 0.00 | — | 44,945 | D | ↗ |
| 2025-05-22 | TANNENBAUM RENEE P | Director | A-Award | A | Common Stock | 4,336 | 0.00 | — | 26,957 | D | ↗ |
| 2025-05-22 | Pera Antonio R | Director | A-Award | A | Common Stock | 4,336 | 0.00 | — | 35,373 | D | ↗ |
| 2025-05-22 | Leonard Matthew J | Director | A-Award | A | Common Stock | 4,336 | 0.00 | — | 16,329 | D | ↗ |
| 2025-05-22 | HAUGHEY THOMAS | Director | A-Award | A | Common Stock | 4,336 | 0.00 | — | 55,862 | D | ↗ |
| 2025-05-15 | Gutwerg Ori | Officer | S-Sale | D | Common Stock | 881 | 60.07 | 52.9K | 89,897 | D | ↗ |
| 2025-05-14 | Mutz Christopher | Officer | S-Sale | D | Common Stock | 4,000 | 60.45 | 241.8K | 107,317 | D | ↗ |
| 2025-05-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 400 | 62.20 | 24.9K | 79,745 | D | ↗ |
| 2025-05-09 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 700 | 76.83 | 53.8K | 631,920 | I | ↗ |
| 2025-04-14 | Cook Meredith | Officer | S-Sale | D | Common Stock | 400 | 68.96 | 27.6K | 80,145 | D | ↗ |
| 2025-03-23 | Lalwani Nikhil | Director / Officer | F-InKind | D | Common Stock | 17,455 | 64.26 | 1.12M | 468,179 | D | ↗ |
| 2025-03-23 | CAREY STEPHEN P. | Officer | F-InKind | D | Common Stock | 6,210 | 64.26 | 399.1K | 180,863 | D | ↗ |
| 2025-03-19 | Davis Krista | Officer | S-Sale | D | Common Stock | 1,866 | 65.00 | 121.3K | 64,659 | D | ↗ |
| 2025-03-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 400 | 63.33 | 25.3K | 80,545 | D | ↗ |
| 2025-03-07 | Mutz Christopher | Officer | F-InKind | D | Common Stock | 2,874 | 60.62 | 174.2K | 111,317 | D | ↗ |
| 2025-03-07 | Lalwani Nikhil | Director / Officer | F-InKind | D | Common Stock | 17,060 | 60.62 | 1.03M | 485,634 | D | ↗ |
| 2025-03-07 | Gutwerg Ori | Officer | F-InKind | D | Common Stock | 3,314 | 60.62 | 200.9K | 90,778 | D | ↗ |
| 2025-03-07 | Davis Krista | Officer | S-Sale | D | Common Stock | 1,000 | 60.86 | 60.9K | 66,525 | D | ↗ |
| 2025-03-07 | CAREY STEPHEN P. | Officer | F-InKind | D | Common Stock | 5,150 | 60.62 | 312.2K | 187,073 | D | ↗ |
| 2025-03-05 | Gutwerg Ori | Officer | M-Exempt | A | Common Stock | 300 | 31.49 | 9.4K | 99,476 | D | ↗ |
| 2025-02-28 | Rowland Thomas Andrew | Officer | F-InKind | D | Common Stock | 627 | 61.89 | 38.8K | 45,465 | D | ↗ |
| 2025-02-28 | Mutz Christopher | Officer | F-InKind | D | Common Stock | 1,275 | 61.89 | 78.9K | 114,191 | D | ↗ |
| 2025-02-28 | Lalwani Nikhil | Director / Officer | F-InKind | D | Common Stock | 12,216 | 61.89 | 756.0K | 502,694 | D | ↗ |
| 2025-02-28 | Gutwerg Ori | Officer | F-InKind | D | Common Stock | 1,570 | 61.89 | 97.2K | 99,176 | D | ↗ |
| 2025-02-28 | Davis Krista | Officer | F-InKind | D | Common Stock | 1,099 | 61.89 | 68.0K | 67,525 | D | ↗ |
| 2025-02-28 | Cook Meredith | Officer | F-InKind | D | Common Stock | 1,099 | 61.89 | 68.0K | 80,945 | D | ↗ |
| 2025-02-28 | CAREY STEPHEN P. | Officer | F-InKind | D | Common Stock | 1,861 | 61.89 | 115.2K | 192,223 | D | ↗ |
| 2025-02-21 | Davis Krista | Officer | S-Sale | D | Common Stock | 1,000 | 60.20 | 60.2K | 68,624 | D | ↗ |
| 2025-02-15 | Mutz Christopher | Officer | F-InKind | D | Common Stock | 1,184 | 58.92 | 69.8K | 115,466 | D | ↗ |
| 2025-02-15 | Gutwerg Ori | Officer | F-InKind | D | Common Stock | 1,167 | 58.92 | 68.8K | 100,746 | D | ↗ |
| 2025-02-14 | Rowland Thomas Andrew | Officer | F-InKind | D | Common Stock | 582 | 58.92 | 34.3K | 46,092 | D | ↗ |
| 2025-02-14 | Mutz Christopher | Officer | F-InKind | D | Common Stock | 1,473 | 58.92 | 86.8K | 116,650 | D | ↗ |
| 2025-02-14 | Lalwani Nikhil | Director / Officer | F-InKind | D | Common Stock | 7,799 | 58.92 | 459.5K | 514,910 | D | ↗ |
| 2025-02-14 | Gutwerg Ori | Officer | F-InKind | D | Common Stock | 1,426 | 58.92 | 84.0K | 101,913 | D | ↗ |
| 2025-02-14 | Davis Krista | Officer | F-InKind | D | Common Stock | 1,196 | 58.92 | 70.5K | 69,624 | D | ↗ |
| 2025-02-14 | Cook Meredith | Officer | F-InKind | D | Common Stock | 1,434 | 58.92 | 84.5K | 82,044 | D | ↗ |
| 2025-02-14 | CAREY STEPHEN P. | Officer | F-InKind | D | Common Stock | 1,730 | 58.92 | 101.9K | 194,084 | D | ↗ |
| 2025-02-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 400 | 59.54 | 23.8K | 83,478 | D | ↗ |
| 2025-02-12 | Shanmugam Muthusamy | Director / Officer | A-Award | A | Common Stock | 9,574 | 0.00 | — | 92,588 | D | ↗ |
| 2025-02-12 | Rowland Thomas Andrew | Officer | A-Award | A | Common Stock | 7,834 | 0.00 | — | 41,452 | D | ↗ |
| 2025-02-12 | Mutz Christopher | Officer | A-Award | A | Common Stock | 24,808 | 0.00 | — | 101,585 | D | ↗ |
| 2025-02-12 | Lalwani Nikhil | Director / Officer | A-Award | A | Common Stock | 91,399 | 0.00 | — | 461,777 | D | ↗ |
| 2025-02-12 | Gutwerg Ori | Officer | A-Award | A | Common Stock | 10,444 | 0.00 | — | 103,339 | D | ↗ |
| 2025-02-12 | Gassert Chad | Officer | A-Award | A | Common Stock | 14,362 | 0.00 | — | 64,041 | D | ↗ |
| 2025-02-12 | Davis Krista | Officer | A-Award | A | Common Stock | 13,057 | 0.00 | — | 62,116 | D | ↗ |
| 2025-02-12 | Cook Meredith | Officer | A-Award | A | Common Stock | 11,316 | 0.00 | — | 83,878 | D | ↗ |
| 2025-02-12 | CAREY STEPHEN P. | Officer | A-Award | A | Common Stock | 16,538 | 0.00 | — | 195,814 | D | ↗ |
| 2025-01-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 400 | 53.92 | 21.6K | 55,588 | D | ↗ |
| 2024-12-17 | CAREY STEPHEN P. | Officer | S-Sale | D | Common Stock | 7,500 | 55.79 | 418.4K | 154,468 | D | ↗ |
| 2024-12-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 250 | 56.24 | 14.1K | 55,988 | D | ↗ |
| 2024-12-11 | Davis Krista | Officer | S-Sale | D | Common Stock | 1,000 | 60.00 | 60.0K | 49,059 | D | ↗ |
| 2024-11-26 | Lalwani Nikhil | Director / Officer | S-Sale | D | Common Stock | 3,481 | 58.30 | 202.9K | 370,378 | D | ↗ |
| 2024-11-15 | Rowland Thomas Andrew | Officer | F-InKind | D | Common Stock | 867 | 56.58 | 49.1K | 33,169 | D | ↗ |
| 2024-11-15 | Mutz Christopher | Officer | S-Sale | D | Common Stock | 6,500 | 57.70 | 375.1K | 76,777 | D | ↗ |
| 2024-11-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 250 | 61.36 | 15.3K | 56,238 | D | ↗ |
| 2024-10-14 | Cook Meredith | Officer | S-Sale | D | Common Stock | 250 | 57.19 | 14.3K | 56,488 | D | ↗ |
| 2024-09-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 250 | 56.82 | 14.2K | 56,738 | — | ↗ |
| 2024-09-12 | Davis Krista | Officer | F-InKind | D | Common Stock | 1,486 | 56.15 | 83.4K | 50,059 | — | ↗ |
| 2024-09-08 | Lalwani Nikhil | Director / Officer | F-InKind | D | Common Stock | 3,646 | 60.51 | 220.6K | 373,859 | — | ↗ |
| 2024-08-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 250 | 59.62 | 14.9K | 56,988 | — | ↗ |
| 2024-07-18 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 2,743 | 62.00 | 170.1K | 632,620 | — | ↗ |
| 2024-07-18 | Cook Meredith | Officer | F-InKind | D | Common Stock | 1,743 | 61.35 | 106.9K | 57,238 | — | ↗ |
| 2024-07-17 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 14,257 | 63.16 | 900.5K | 635,363 | — | ↗ |
| 2024-07-16 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 22,000 | 64.27 | 1.41M | 649,620 | — | ↗ |
| 2024-07-15 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 11,000 | 63.38 | 697.2K | 671,620 | — | ↗ |
| 2024-07-12 | Cook Meredith | Officer | S-Sale | D | Common Stock | 250 | 64.91 | 16.2K | 58,981 | — | ↗ |
| 2024-07-01 | Gassert Chad | Officer | S-Sale | D | Common Stock | 20,000 | 63.44 | 1.27M | 193,226 | — | ↗ |
| 2024-06-21 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 20,000 | 58.90 | 1.18M | 682,620 | — | ↗ |
| 2024-06-20 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 11,447 | 59.86 | 685.2K | 702,620 | — | ↗ |
| 2024-06-18 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 10,607 | 60.76 | 644.5K | 714,067 | — | ↗ |
| 2024-06-17 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 7,946 | 61.41 | 488.0K | 724,674 | — | ↗ |
| 2024-06-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 250 | 63.80 | 16.0K | 59,231 | — | ↗ |
| 2024-06-07 | Marken James G. | Officer | M-Exempt | D | Stock Option (right to buy) | 7,250 | 49.51 | 358.9K | 0 | — | ↗ |
| 2024-06-05 | Gutwerg Ori | Officer | S-Sale | D | Common Stock | 2,985 | 67.00 | 200.0K | 77,227 | — | ↗ |
| 2024-06-04 | CAREY STEPHEN P. | Officer | S-Sale | D | Common Stock | 5,000 | 63.58 | 317.9K | 161,968 | — | ↗ |
| 2024-06-03 | Gassert Chad | Officer | S-Sale | D | Common Stock | 20,000 | 64.41 | 1.29M | 213,226 | — | ↗ |
| 2024-05-21 | Walsh Patrick D | Director | A-Award | A | Common Stock | 4,410 | 0.00 | — | 74,712 | — | ↗ |
| 2024-05-21 | Thoma Jeanne | Director | A-Award | A | Common Stock | 4,410 | 0.00 | — | 40,609 | — | ↗ |
| 2024-05-21 | TANNENBAUM RENEE P | Director | A-Award | A | Common Stock | 4,410 | 0.00 | — | 22,621 | — | ↗ |
| 2024-05-21 | Pera Antonio R | Director | A-Award | A | Common Stock | 4,410 | 0.00 | — | 31,037 | — | ↗ |
| 2024-05-21 | Mutz Christopher | Officer | S-Sale | D | Common Stock | 2,000 | 61.61 | 123.2K | 83,277 | — | ↗ |
| 2024-05-21 | Leonard Matthew J | Director | A-Award | A | Common Stock | 4,410 | 0.00 | — | 11,993 | — | ↗ |
| 2024-05-21 | HAUGHEY THOMAS | Director | A-Award | A | Common Stock | 4,410 | 0.00 | — | 51,526 | — | ↗ |
| 2024-05-20 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 12,855 | 61.81 | 794.6K | 732,620 | — | ↗ |
| 2024-05-17 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 5,836 | 62.09 | 362.4K | 745,475 | — | ↗ |
| 2024-05-16 | TANNENBAUM RENEE P | Director | S-Sale | D | Common Stock | 2,000 | 63.87 | 127.7K | 18,211 | — | ↗ |
| 2024-05-16 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 16,459 | 63.84 | 1.05M | 751,311 | — | ↗ |
| 2024-05-15 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 14,850 | 65.86 | 978.0K | 767,770 | — | ↗ |
| 2024-05-14 | Lalwani Nikhil | Director / Officer | S-Sale | D | Common Stock | 16,669 | 66.10 | 1.10M | 377,505 | — | ↗ |
| 2024-05-13 | Cook Meredith | Officer | S-Sale | D | Common Stock | 250 | 67.69 | 16.9K | 59,481 | — | ↗ |
| 2024-05-01 | Gassert Chad | Officer | S-Sale | D | Common Stock | 20,000 | 66.62 | 1.33M | 233,226 | — | ↗ |
| 2024-04-19 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 16,809 | 65.17 | 1.10M | 782,620 | — | ↗ |
| 2024-04-18 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 10,423 | 64.98 | 677.3K | 799,429 | — | ↗ |
| 2024-04-17 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 9,520 | 65.40 | 622.6K | 809,852 | — | ↗ |
| 2024-04-16 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 5,834 | 66.20 | 386.2K | 819,372 | — | ↗ |
| 2024-04-15 | Shanmugam Muthusamy | Director / Officer | S-Sale | D | Common Stock | 7,414 | 66.33 | 491.8K | 825,206 | — | ↗ |
| 2024-04-12 | Cook Meredith | Officer | S-Sale | D | Common Stock | 250 | 67.79 | 16.9K | 59,731 | — | ↗ |
| 2024-04-10 | Marken James G. | Officer | F-InKind | D | Common Stock | 2,799 | 66.96 | 187.4K | 116,006 | — | ↗ |
| 2024-04-10 | CAREY STEPHEN P. | Officer | F-InKind | D | Common Stock | 4,534 | 66.96 | 303.6K | 166,968 | — | ↗ |
| 2024-04-01 | Gassert Chad | Officer | S-Sale | D | Common Stock | 20,000 | 67.25 | 1.35M | 253,226 | — | ↗ |
| 2024-03-28 | Rowland Thomas Andrew | Officer | — | D | Common Stock | 0 | 0.00 | — | 34,036 | — | ↗ |
| 2024-03-23 | Marken James G. | Officer | F-InKind | D | Common Stock | 3,653 | 69.58 | 254.2K | 118,805 | — | ↗ |
| 2024-03-23 | Lalwani Nikhil | Director / Officer | F-InKind | D | Common Stock | 17,455 | 69.58 | 1.21M | 394,174 | — | ↗ |
| 2024-03-23 | CAREY STEPHEN P. | Officer | F-InKind | D | Common Stock | 6,210 | 69.58 | 432.1K | 171,502 | — | ↗ |
Executive team
Top executives
EBIT / Employee
119.4K
Shares Outstanding
22.75M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Nikhil Lalwani President and Chief Executive Officer | 837.4K | — | 7.85M | — | 1.57M | 20.0K | 10.28M | 76.36% | ↗ |
| 2 | 2025 | Christopher K. Mutz Senior Vice President, Head of Rare Disease | 471.6K | — | 2.13M | — | 477.8K | 317.0K | 3.40M | 62.72% | ↗ |
| 3 | 2025 | Stephen P. Carey Senior Vice President, Finance and Chief Financial Officer | 521.0K | — | 2.13M | — | 582.9K | 17.6K | 3.25M | 65.51% | ↗ |
| 4 | 2025 | Meredith W. Cook Senior Vice President, General Counsel and Corporate Secretary | 462.1K | — | 1.46M | — | 382.0K | 16.7K | 2.32M | 62.87% | ↗ |
| 5 | 2025 | Ori Gutwerg Senior Vice President, Generics | 479.9K | — | 1.35M | — | 484.3K | — | 2.31M | 58.25% | ↗ |
| 6 | 2024 | Nikhil Lalwani President and Chief Executive Officer | 794.9K | — | 6.42M | — | 1.61M | 37.8K | 8.86M | 72.47% | ↗ |
| 7 | 2024 | Stephen P. Carey Senior Vice President and Chief Financial Officer | 509.9K | — | 1.71M | — | 611.8K | 16.8K | 2.85M | 60.06% | ↗ |
| 8 | 2024 | Stephen P. Carey Senior Vice President, Finance and Chief Financial Officer | 509.9K | — | 1.71M | — | 611.8K | 16.8K | 2.85M | 60.06% | ↗ |
| 9 | 2024 | Christopher K. Mutz Senior Vice President, Head of Rare Disease | 447.9K | — | 1.50M | — | 455.0K | 16.8K | 2.42M | 61.96% | ↗ |
| 10 | 2024 | Ori Gutwerg Senior Vice President, Generics | 463.1K | — | 1.18M | — | 467.9K | — | 2.11M | 55.84% | ↗ |
| 11 | 2024 | Meredith W. Cook Senior Vice President, General Counsel and Corporate Secretary | 408.7K | — | 1.18M | — | 420.0K | 16.8K | 2.02M | 58.19% | ↗ |
| 12 | 2023 | Nikhil Lalwani President and Chief Executive Officer | 764.3K | — | 5.76M | — | 1.54M | 13.2K | 8.08M | 71.25% | ↗ |
| 13 | 2023 | Stephen P. Carey Senior Vice President and Chief Financial Officer | 509.9K | — | 1.47M | — | 584.3K | 16.8K | 2.58M | 56.87% | ↗ |
| 14 | 2023 | Stephen P. Carey Senior Vice President, Finance and Chief Financial Officer | 509.9K | — | 1.47M | — | 584.3K | 16.8K | 2.58M | 56.87% | ↗ |
| 15 | 2023 | Ori Gutwerg Senior Vice President, Generics | 445.3K | — | 1.05M | — | 449.9K | — | 1.94M | 53.90% | ↗ |
| 16 | 2023 | Christopher K. Mutz Senior Vice President, Head of Rare Disease | 424.1K | — | 1.05M | — | 428.5K | 15.4K | 1.91M | 54.66% | ↗ |
| 17 | 2023 | Chad Ga ssert Senior Vice President, Corporate Development and Strategy | 429.2K | — | 1.05M | — | 413.1K | 7.4K | 1.90M | 55.19% | ↗ |
| 18 | 2022 | Nikhil Lalwani President and Chief Executive Officer | 736.8K | — | 3.81M | — | 557.0K | 12.2K | 5.11M | 74.45% | ↗ |
| 19 | 2022 | Stephen P. Carey Senior Vice President and Chief Financial Officer | 505.9K | — | 1.29M | — | 229.4K | 15.7K | 2.04M | 63.18% | ↗ |
| 20 | 2022 | James G. Marken Senior Vice President, Operations and Product Development | 454.8K | 206.3K | 758.3K | — | — | 12.2K | 1.43M | 52.97% | ↗ |
| 21 | 2022 | Ori Gutwerg Senior Vice President, Generics | 429.2K | — | 739.0K | — | 194.7K | — | 1.36M | 54.22% | ↗ |
| 22 | 2022 | Christopher K. Mutz Senior Vice President, Head of Rare Disease | 408.8K | — | 739.0K | — | 144.2K | 12.2K | 1.30M | 56.67% | ↗ |
| 23 | 2021 | Nikhil Lalwani President and Chief Executive Officer | 715.3K | — | 4.37M | — | 1.44M | 14.5K | 6.54M | 66.80% | ↗ |
| 24 | 2021 | Stephen P. Carey Senior Vice President, Finance and Chief Financial Officer | 491.3K | 594.0K | 1.74M | — | — | 21.7K | 2.85M | 61.17% | ↗ |
| 25 | 2021 | Stephen P. Carey Senior Vice President and Chief Financial Officer | 491.3K | — | 1.74M | — | 594.0K | 21.7K | 2.85M | 61.17% | ↗ |
| 26 | 2021 | James G. Marken Senior Vice President, Operations and Product Development | 440.0K | 255.9K | 1.03M | — | — | 13.1K | 1.73M | 59.13% | ↗ |
| 27 | 2021 | Christopher K. Mutz Head of Rare Disease | 338.5K | 247.5K | 508.1K | 502.7K | — | 9.2K | 1.61M | 62.94% | ↗ |
| 28 | 2021 | Christopher K. Mutz Senior Vice President, Head of Rare Disease | 338.5K | — | 508.1K | 502.7K | 247.5K | 9.2K | 1.61M | 62.94% | ↗ |
| 29 | 2021 | Ori Gutwerg Senior Vice President, Generics | 355.4K | 134.0K | 406.4K | 402.2K | 221.4K | — | 1.52M | 53.22% | ↗ |
| 30 | 2020 | Nikhil Lalwani President and Chief Executive Officer | 199.2K | 210.0K | 826.7K | 2.48M | — | — | 3.72M | 88.98% | ↗ |
| 31 | 2020 | Stephen P. Carey Senior Vice President and Chief Financial Officer | 474.3K | 388.8K | 1.88M | — | — | 14.1K | 2.75M | 68.16% | ↗ |
| 32 | 2020 | Stephen P. Carey Senior Vice President, Finance and Chief Financial Officer | 474.3K | 388.8K | 1.88M | — | — | 14.1K | 2.75M | 68.16% | ↗ |
| 33 | 2020 | Robert W. Schrepfer Former Senior Vice President, New Business Development and Specialty Sales | 474.3K | 288.8K | 1.88M | — | — | 18.5K | 2.66M | 70.61% | ↗ |
| 34 | 2020 | James G. Marken Senior Vice President, Operations and Product Development | 426.3K | 276.3K | 1.16M | — | — | 13.1K | 1.87M | 61.82% | ↗ |
| 35 | 2020 | Patrick D. Walsh Former Interim President and Chief Executive Officer | 282.8K | — | 679.3K | — | — | 145.00 | 962.2K | 70.60% | ↗ |
| 36 | 2020 | Arthur S. Przybyl Former President and Chief Executive Officer | 332.8K | — | — | — | — | 525.0K | 857.8K | 0.00% | ↗ |
| 37 | 2019 | Arthur S. Przybyl President, Chief Executive Officer and Director | 776.8K | — | 2.48M | 1.83M | 703.4K | 33.8K | 5.82M | 73.97% | ↗ |
| 38 | 2019 | Arthur S. Przybyl Former President and Chief Executive Officer | 776.8K | 703.4K | 2.48M | 1.83M | — | 33.8K | 5.82M | 73.97% | ↗ |
| 39 | 2019 | Robert W. Schrepfer Former Senior Vice President, New Business Development and Specialty Sales | 456.9K | 252.1K | 826.6K | 610.1K | — | 15.3K | 2.16M | 66.48% | ↗ |
| 40 | 2019 | Robert W. Schrepfer Senior Vice President, New Business Development and Specialty Sales | 456.9K | — | 826.6K | 610.1K | 252.1K | 15.3K | 2.16M | 66.48% | ↗ |
| 41 | 2019 | Stephen P. Carey Senior Vice President, Finance and Chief Financial Officer | 456.9K | 252.1K | 826.6K | 610.1K | — | 10.7K | 2.16M | 66.63% | ↗ |
| 42 | 2019 | Stephen P. Carey Vice President, Finance and Chief Financial Officer | 456.9K | — | 826.6K | 610.1K | 252.1K | 10.7K | 2.16M | 66.63% | ↗ |
| 43 | 2019 | James G. Marken Senior Vice President, Operations and Product Development | 410.6K | 185.4K | 454.6K | 335.5K | — | 12.5K | 1.40M | 56.49% | ↗ |
| 44 | 2018 | Arthur S. Przybyl Former President and Chief Executive Officer | 726.9K | 675.0K | 1.66M | 1.10M | — | 30.6K | 4.20M | 65.87% | ↗ |
| 45 | 2018 | Arthur S. Przybyl President, Chief Executive Officer and Director | 726.9K | — | 1.66M | 1.10M | 675.0K | 30.6K | 4.20M | 65.87% | ↗ |
| 46 | 2018 | Robert W. Schrepfer Senior Vice President, New Business Development and Specialty Sales | 431.2K | — | 456.5K | 301.3K | 240.3K | 14.9K | 1.44M | 52.48% | ↗ |
| 47 | 2018 | Robert W. Schrepfer Former Senior Vice President, New Business Development and Specialty Sales | 431.2K | 240.3K | 456.5K | 301.3K | — | 14.9K | 1.44M | 52.48% | ↗ |
| 48 | 2018 | Stephen P. Carey Vice President, Finance and Chief Financial Officer | 431.2K | — | 456.5K | 301.3K | 240.3K | 9.5K | 1.44M | 52.67% | ↗ |
| 49 | 2018 | Stephen P. Carey Senior Vice President, Finance and Chief Financial Officer | 431.2K | 240.3K | 456.5K | 301.3K | — | 9.5K | 1.44M | 52.67% | ↗ |
| 50 | 2018 | James G. Marken Senior Vice President, Operations and Product Development | 387.7K | 192.0K | 251.1K | 166.4K | — | 12.5K | 1.01M | 41.35% | ↗ |
| 51 | 2017 | Arthur S. Przybyl President, Chief Executive Officer and Director | 647.3K | — | 1.18M | 1.22M | 506.3K | 27.3K | 3.58M | 67.02% | ↗ |
| 52 | 2017 | Stephen P. Carey Vice President, Finance and Chief Financial Officer | 389.2K | — | 328.0K | 341.3K | 180.0K | 8.0K | 1.25M | 53.69% | ↗ |
| 53 | 2017 | Robert W. Schrepfer Senior Vice President, New Business Development and Specialty Sales | 385.5K | — | 328.0K | 341.3K | 180.0K | 10.5K | 1.25M | 53.75% | ↗ |
| 54 | 2017 | Robert Schrepfer Senior Vice President, New Business Development and Specialty Sales | 385.5K | — | 328.0K | 341.3K | 180.0K | 10.5K | 1.25M | 53.75% | ↗ |
| 55 | 2017 | James G. Marken Senior Vice President, Operations and Product Development | 353.3K | — | 179.5K | 186.8K | 144.0K | 11.9K | 875.5K | 41.83% | ↗ |
| 56 | 2016 | Arthur S. Przybyl President, Chief Executive Officer and Director | 572.0K | 57.2K | 761.1K | 751.5K | 343.2K | 29.1K | 2.51M | 60.16% | ↗ |
| 57 | 2016 | Charlotte C. Arnold Vice President, Finance and Chief Financial Officer | 140.1K | — | 170.5K | 160.3K | — | 1.40M | 1.87M | 17.71% | ↗ |
| 58 | 2016 | Stephen P. Carey Vice President, Finance and Chief Financial Officer | 229.8K | — | — | 1.15M | 96.0K | — | 1.47M | 77.87% | ↗ |
| 59 | 2016 | Robert W. Schrepfer Senior Vice President, New Business Development and Specialty Sales | 325.3K | — | 192.8K | 190.4K | 138.5K | 11.9K | 858.9K | 44.61% | ↗ |
| 60 | 2016 | Robert Schrepfer Senior Vice President, New Business Development and Specialty Sales | 325.3K | — | 192.8K | 190.4K | 138.5K | 11.9K | 858.9K | 44.61% | ↗ |
| 61 | 2016 | James G. Marken Senior Vice President, Operations and Product Development | 315.1K | 46.8K | 76.1K | 75.2K | 117.3K | 11.9K | 642.3K | 23.55% | ↗ |
| 62 | 2015 | Arthur S. Przybyl President, Chief Executive Officer and Director | 568.3K | — | 1.03M | 998.4K | 343.2K | 10.0K | 2.95M | 68.77% | ↗ |
| 63 | 2015 | Charlotte C. Arnold Vice President, Finance and Chief Financial Officer | 368.8K | — | 288.6K | 266.2K | 148.0K | — | 1.07M | 51.77% | ↗ |
| 64 | 2015 | Robert Schrepfer Senior Vice President, New Business Development and Specialty Sales | 300.3K | — | 206.1K | 199.7K | 120.4K | — | 826.5K | 49.10% | ↗ |
| 65 | 2015 | Robert Schrepfer Vice President, New Business Development and Contract Manufacturing | 300.3K | — | 206.1K | 199.7K | 120.4K | — | 826.5K | 49.10% | ↗ |
| 66 | 2015 | James G. Marken Vice President, Operations | 293.6K | — | 103.1K | 99.8K | 87.5K | — | 584.0K | 34.74% | ↗ |
| 67 | 2015 | James G. Marken Senior Vice President, Operations and Product Development | 293.6K | — | 103.1K | 99.8K | 87.5K | — | 584.0K | 34.74% | ↗ |
| 68 | 2014 | Arthur S. Przybyl President, Chief Executive Officer and Director | 461.5K | — | 379.0K | 454.2K | 447.3K | 10.0K | 1.75M | 47.56% | ↗ |
| 69 | 2014 | Arthur S. Przybyl President, Chief Executive Officer and Director | 461.5K | — | 379.0K | 454.2K | 447.3K | 10.0K | 1.75M | 47.56% | ↗ |
| 70 | 2014 | Robert Schrepfer Senior Vice President, New Business Development and Specialty Sales | 259.2K | — | 148.1K | 556.9K | 159.0K | — | 1.12M | 62.77% | ↗ |
| 71 | 2014 | Robert Schrepfer Vice President, New Business Development and Contract Manufacturing | 259.2K | — | 148.1K | 556.9K | 159.0K | — | 1.12M | 62.77% | ↗ |
| 72 | 2014 | Robert Schrepfer Vice President, New Business Development and Contract Manufacturing | 259.2K | — | 148.1K | 556.9K | 159.0K | — | 1.12M | 62.77% | ↗ |
| 73 | 2014 | Charlotte C. Arnold Vice President, Finance and Chief Financial Officer | 303.1K | — | 177.7K | 213.7K | 195.0K | — | 889.5K | 44.00% | ↗ |
| 74 | 2014 | Charlotte C. Arnold Vice President, Finance and Chief Financial Officer | 303.1K | — | 177.7K | 213.7K | 195.0K | — | 889.5K | 44.00% | ↗ |
| 75 | 2014 | James G. Marken Senior Vice President, Operations and Product Development | 259.5K | — | 97.7K | 115.8K | 119.3K | — | 592.2K | 36.05% | ↗ |
| 76 | 2014 | James G. Marken Vice President, Operations | 259.5K | — | 97.7K | 115.8K | 119.3K | — | 592.2K | 36.05% | ↗ |
| 77 | 2013 | Arthur S. Przybyl President, Chief Executive Officer and Director | 200.5K | 200.0K | 2.40M | 2.33M | 187.7K | 5.3K | 5.32M | 88.84% | ↗ |
| 78 | 2013 | Arthur S. Przybyl President, Chief Executive Officer and Director | 200.5K | 200.0K | 2.40M | 2.33M | 187.7K | 5.3K | 5.32M | 88.84% | ↗ |
| 79 | 2013 | Charlotte C. Arnold Vice President, Finance and Chief Financial Officer | 133.6K | 100.0K | 726.2K | 1.08M | 100.0K | — | 2.14M | 84.39% | ↗ |
| 80 | 2013 | Charlotte C. Arnold Vice President, Finance and Chief Financial Officer | 133.6K | 100.0K | 726.2K | 1.08M | 100.0K | — | 2.14M | 84.39% | ↗ |
| 81 | 2013 | Stephen M. Simes Former Vice Chairman, President and Chief Executive Officer | 382.6K | — | — | — | — | 1.52M | 1.90M | 0.00% | ↗ |
| 82 | 2013 | James G. Marken Vice President, Operations | 131.4K | — | 531.0K | 718.3K | 73.8K | — | 1.45M | 85.89% | ↗ |
| 83 | 2013 | Robert Schrepfer Vice President, New Business Development and Contract Manufacturing | 91.4K | — | — | 1.12M | 98.0K | — | 1.30M | 85.48% | ↗ |
| 84 | 2013 | Robert Schrepfer Vice President, New Business Development and Contract Manufacturing | 91.4K | — | — | 1.12M | 98.0K | — | 1.30M | 85.48% | ↗ |
| 85 | 2013 | Phillip B. Donenberg Former Senior Vice President of Finance, Chief Financial Officer and Secretary | 172.4K | — | — | — | — | 793.7K | 966.1K | 0.00% | ↗ |
| 86 | 2013 | Charlotte C. Arnold Vice President and Chief Financial Officer | 133.6K | 100.0K | 627.3K | — | 100.0K | — | 960.5K | 65.31% | ↗ |
| 87 | 2013 | Robert J. Jamnick Vice President, Quality and Product Development | 112.6K | — | 502.6K | — | 63.2K | — | 678.3K | 74.09% | ↗ |
| 88 | 2012 | Stephen M. Simes Former Vice Chairman, President and Chief Executive Officer | 496.7K | — | — | 420.0K | 200.0K | 31.7K | 1.15M | 36.57% | ↗ |
| 89 | 2012 | Phillip B. Donenberg Former Senior Vice President of Finance, Chief Financial Officer and Secretary | 308.0K | — | — | 149.6K | 100.0K | 28.1K | 585.7K | 25.54% | ↗ |
| 90 | 2011 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 496.7K | — | — | 695.5K | 302.5K | 38.7K | 1.53M | 45.36% | ↗ |
| 91 | 2011 | Phillip B. Donenberg Senior Vice President of Finance, Chief Financial Officer and Secretary | 308.0K | — | — | 288.9K | 122.4K | 27.4K | 746.6K | 38.69% | ↗ |
| 92 | 2011 | Michael C. Snabes, M.D., Ph.D. Senior Vice President of Medical Affairs | 376.0K | — | — | 128.4K | 98.7K | 18.2K | 621.3K | 20.67% | ↗ |
| 93 | 2010 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 486.2K | 270.9K | — | 156.0K | — | 36.2K | 949.4K | 16.43% | ↗ |
| 94 | 2010 | Phillip B. Donenberg Senior Vice President of Finance, Chief Financial Officer and Secretary | 285.6K | 112.0K | — | 104.0K | — | 28.7K | 530.2K | 19.61% | ↗ |
| 95 | 2010 | Michael C. Snabes, M.D., Ph.D. Senior Vice President of Medical Affairs | 374.5K | 109.5K | — | 26.0K | — | 18.2K | 528.2K | 4.92% | ↗ |
| 96 | 2010 | Michael C. Snabes, M.D., Ph.D. Senior Vice President of Medical Affairs | 374.5K | 109.5K | — | — | — | 18.2K | 528.2K | 0.00% | ↗ |
| 97 | 2009 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 417.6K | 275.0K | — | 300.0K | — | 37.2K | 1.04M | 28.88% | ↗ |
| 98 | 2009 | Phillip B. Donenberg Senior Vice President of Finance, Chief Financial Officer and Secretary | 232.1K | 175.0K | — | 128.8K | — | 2.2K | 557.4K | 23.10% | ↗ |
| 99 | 2009 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 232.1K | 175.0K | — | — | — | 21.5K | 557.2K | 0.00% | ↗ |
| 100 | 2008 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 417.6K | — | — | 271.3K | — | 30.9K | 719.9K | 37.69% | ↗ |
| 101 | 2008 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 417.6K | — | — | — | — | 30.9K | 697.5K | 0.00% | ↗ |
| 102 | 2008 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 232.1K | — | — | 174.1K | — | 20.1K | 426.4K | 40.83% | ↗ |
| 103 | 2008 | Phillip B. Donenberg Senior Vice President of Finance, Chief Financial Officer and Secretary | 232.1K | — | — | — | — | 20.1K | 401.7K | 0.00% | ↗ |
| 104 | 2008 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 232.1K | — | — | — | — | 20.1K | 401.7K | 0.00% | ↗ |
| 105 | 2007 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 394.0K | 256.1K | — | — | — | 41.9K | 1.26M | 0.00% | ↗ |
| 106 | 2007 | Stephen M. Simes Vice Chairman, President | 394.0K | 256.1K | — | — | — | 41.9K | 880.3K | 0.00% | ↗ |
| 107 | 2007 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 394.0K | 256.1K | — | 188.3K | — | 41.9K | 880.3K | 21.39% | ↗ |
| 108 | 2007 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 219.0K | 87.6K | — | 185.2K | — | 19.1K | 510.9K | 36.24% | ↗ |
| 109 | 2007 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 219.0K | 87.6K | — | — | — | 19.1K | 438.7K | 0.00% | ↗ |
| 110 | 2006 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 374.4K | 140.4K | — | 86.0K | — | 40.3K | 641.2K | 13.42% | ↗ |
| 111 | 2006 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 374.4K | 140.4K | — | 86.0K | — | 40.3K | 641.2K | 13.42% | ↗ |
| 112 | 2006 | Stephen M. Simes Vice Chairman, President | 374.4K | 140.4K | — | — | — | 40.3K | 641.2K | 0.00% | ↗ |
| 113 | 2006 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 208.6K | 41.7K | — | 127.6K | — | 14.7K | 392.6K | 32.51% | ↗ |
| 114 | 2005 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 374.4K | — | — | — | — | 33.9K | 408.3K | 0.00% | ↗ |
| 115 | 2005 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 198.6K | 150.0K | — | — | — | — | 348.6K | 0.00% | ↗ |
| 116 | 2005 | Leah M. Lehman, Ph.D. Former Vice President, Product Development | 249.6K | — | — | — | — | — | 249.6K | 0.00% | ↗ |
| 117 | 2005 | Steven J. Bell, Ph.D. Vice President, Research and Pre-Clinical Development | 166.4K | 35.0K | — | 79.2K | — | 14.2K | 215.6K | 36.72% | ↗ |
| 118 | 2004 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 360.0K | 120.0K | — | 126.7K | — | — | 480.0K | 26.39% | ↗ |
| 119 | 2004 | Leah M. Lehman, Ph.D. Former Vice President, Product Development | 240.0K | 40.0K | — | 50.0K | — | 14.3K | 294.3K | 16.99% | ↗ |
| 120 | 2004 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 191.0K | 51.0K | — | — | — | 27.2K | 269.2K | 0.00% | ↗ |
| 121 | 2004 | Leah M. Lehman, Ph.D. Vice President, Product Development | 240.0K | — | — | — | — | 14.8K | 254.8K | 0.00% | ↗ |
| 122 | 2004 | Steven J. Bell, Ph.D. Vice President, Research and Pre-Clinical Development | 160.0K | 32.0K | — | — | — | — | 192.0K | 0.00% | ↗ |
| 123 | 2003 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 323.4K | 161.7K | — | — | — | 34.1K | 519.2K | 0.00% | ↗ |
| 124 | 2003 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 323.4K | 161.7K | — | — | — | 27.2K | 512.3K | 0.00% | ↗ |
| 125 | 2003 | Leah M. Lehman, Ph.D. Vice President, Clinical and Regulatory Affairs | 199.5K | 59.9K | — | — | — | 13.2K | 272.6K | 0.00% | ↗ |
| 126 | 2003 | Leah M. Lehman, Ph.D. Former Vice President, Product Development | 199.5K | 59.9K | — | 25.0K | — | — | 259.4K | 9.64% | ↗ |
| 127 | 2003 | Leah M. Lehman, Ph.D. Vice President, Product Development | 199.5K | 49.9K | — | — | — | — | 249.4K | 0.00% | ↗ |
| 128 | 2003 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 166.2K | 49.9K | — | — | — | 14.3K | 230.4K | 0.00% | ↗ |
| 129 | 2003 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 166.2K | 49.9K | — | 50.0K | — | — | 216.1K | 23.14% | ↗ |
| 130 | 2003 | Steven J. Bell, Ph.D. Vice President, Research and Pre-Clinical Development | 140.0K | 42.0K | — | — | — | 14.8K | 196.8K | 0.00% | ↗ |
| 131 | 2003 | Steven J. Bell, Ph.D. Vice President, Research and Pre-Clinical Development | 140.0K | 42.0K | — | — | — | 12.0K | 194.0K | 0.00% | ↗ |
| 132 | 2002 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 308.0K | 161.7K | — | — | — | 27.2K | 496.9K | 0.00% | ↗ |
| 133 | 2002 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 308.0K | 92.4K | — | — | — | 44.6K | 445.0K | 0.00% | ↗ |
| 134 | 2002 | Leah M. Lehman, Ph.D. Vice President, Clinical and Regulatory Affairs | 190.0K | 34.2K | — | — | — | 12.7K | 236.9K | 0.00% | ↗ |
| 135 | 2002 | Leah M. Lehman, Ph.D. Vice President, Clinical Development | 190.0K | 34.2K | — | 79.1K | — | 12.7K | 236.9K | 33.38% | ↗ |
| 136 | 2002 | Leah M. Lehman, Ph.D. Vice President, Product Development | 190.0K | 28.5K | — | — | — | 14.3K | 232.8K | 0.00% | ↗ |
| 137 | 2002 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 158.3K | 51.0K | — | 79.2K | — | — | 209.3K | 37.82% | ↗ |
| 138 | 2002 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 158.3K | 28.5K | — | — | — | 13.8K | 200.6K | 0.00% | ↗ |
| 139 | 2002 | Steven J. Bell, Ph.D. Vice President, Research and Pre-Clinical Development | 120.0K | 21.6K | — | — | — | 11.5K | 153.1K | 0.00% | ↗ |
| 140 | 2002 | Steven J. Bell, Ph.D. Vice President, Research and Pre-Clinical Development | 120.0K | — | — | — | — | — | 120.0K | 0.00% | ↗ |
| 141 | 2001 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 291.5K | 131.2K | — | — | — | 18.4K | 441.1K | 0.00% | ↗ |
| 142 | 2001 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 291.5K | 131.2K | — | 71.4K | — | 18.4K | 441.1K | 16.19% | ↗ |
| 143 | 2001 | Leah M. Lehman, Ph.D. Vice President, Clinical and Regulatory Affairs | 180.0K | 54.0K | — | — | — | 12.5K | 246.5K | 0.00% | ↗ |
| 144 | 2001 | Leah M. Lehman, Ph.D. Vice President, Clinical Development | 180.0K | 54.0K | — | 50.0K | — | 12.5K | 246.5K | 20.29% | ↗ |
| 145 | 2001 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 150.0K | 45.0K | — | 21.5K | — | 13.6K | 208.6K | 10.33% | ↗ |
| 146 | 2001 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 150.0K | 45.0K | — | — | — | 13.6K | 208.6K | 0.00% | ↗ |
| 147 | 2001 | John E. Lee Former Vice President, Commercial Development | 146.4K | — | — | — | — | 9.3K | 155.7K | 0.00% | ↗ |
| 148 | 2001 | Steven J. Bell, Ph.D. Vice President, Research and Pre-Clinical Development | 102.0K | 30.0K | — | — | — | 11.3K | 143.3K | 0.00% | ↗ |
| 149 | 2001 | Steven J. Bell, Ph.D. Vice President, Research and Pre-Clinical Development | 102.0K | 30.0K | — | 5.0K | — | 11.3K | 143.3K | 3.49% | ↗ |
| 150 | 2000 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 275.0K | 150.0K | — | — | — | 29.3K | 454.3K | 0.00% | ↗ |
| 151 | 2000 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 127.0K | 42.0K | — | — | — | 13.3K | 182.3K | 0.00% | ↗ |
| 152 | 2000 | John E. Lee Former Vice President, Commercial Development | 70.8K | — | — | 500.0K | — | 81.5K | 152.3K | 328.29% | ↗ |
| 153 | 2000 | Steven J. Bell, Ph.D. Vice President, Research and Pre-Clinical Development | 91.5K | 26.0K | — | — | — | 11.3K | 128.8K | 0.00% | ↗ |
| 154 | 2000 | Leah M. Lehman, Ph.D. Vice President, Clinical Development | — | — | — | — | — | — | — | — | ↗ |
| 155 | 1999 | Stephen M. Simes Vice Chairman, President and Chief Executive Officer | 248.9K | 125.0K | — | 1.86M | — | 23.0K | 396.9K | 467.71% | ↗ |
| 156 | 1999 | Phillip B. Donenberg Chief Financial Officer, Treasurer and Secretary | 110.0K | 33.0K | — | 521.9K | — | 13.0K | 156.0K | 334.53% | ↗ |
| 157 | 1999 | Steven J. Bell, Ph.D. Vice President, Research and Pre-Clinical Development | 85.3K | 10.0K | — | 125.0K | — | 6.5K | 101.8K | 122.77% | ↗ |
| 158 | 1999 | John E. Lee Former Vice President, Commercial Development | — | — | — | — | — | — | — | — | ↗ |
| 159 | 1999 | Leah M. Lehman, Ph.D. Vice President, Clinical Development | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nikhil Lalwani | President, Chief Executive Officer & Director | 2M | male |
| Christopher K. Mutz | Senior Vice President & Head of Rare Disease | 1M | male |
| Stephen Carey | Senior Vice President of Finance & Chief Financial Officer | 1M | male |
| Ori Gutwerg | Senior Vice President of Generics | 964.1K | male |
| Meredith W. Cook | Senior Vice President, General Counsel & Corporate Secretary | 860.8K | female |
| Chad Gassert | Senior Vice President of Corporate Development & Strategy | 849.7K | male |
| Muthusamy Shanmugam | Head of R&D, Chief Operating Officer of New Jersey Operations & Director | — | male |
| Mary Pao | Chief Medical Officer | — | — |
| Krista L. Davis | Senior Vice President & Chief Human Resources Officer | — | female |
| Elizabeth Powell | Chief Compliance Officer & Head of Legal of Rare Disease | — | female |
| Thomas Andrew Rowland | Senior Vice President & Head of Established Brands | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ANIP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
